Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the mechanism of action of BTK degraders, highlighting the advantages of this new class of drug in comparison to small molecule inhibitors. Dr Patel also comments on the study of BTK degraders in patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas, who were previously exposed to covalent and non-covalent BTK inhibitors. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Video Rating: / 5

Email This Post Email This Post